Literature DB >> 20540537

(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.

Zhaofei Liu1, Yongjun Yan, Shuanglong Liu, Fan Wang, Xiaoyuan Chen.   

Abstract

Radiolabeled RGD (Arg-Gly-Asp) and bombesin (BBN) radiotracers that specifically target integrin alpha(v)beta(3) and gastrin releasing peptide receptor (GRPR) are both promising radiopharmaceuticals for tumor imaging. We recently designed and synthesized a RGD-BBN heterodimeric peptide with both RGD and BBN motifs in one single molecule. The (18)F-labeled RGD-BBN heterodimer exhibited dual integrin alpha(v)beta(3) and GRPR targeting in a PC-3 prostate cancer model. In this study we investigated whether radiolabeled RGD-BBN tracers can be used to detect breast cancer by using microPET. Cell binding assay demonstrated that the high GRPR expressing breast cancer cells typically express low to moderate level of integrin alpha(v)beta(3), while high integrin alpha(v)beta(3) expressing breast cancer cells have negligible level of GRPR. We labeled RGD-BBN heterodimer with three positron emitting radionuclides (18)F, (64)Cu, and (68)Ga and investigated the corresponding PET radiotracers in both orthotopic T47D (GRPR(+)/low integrin alpha(v)beta(3)) and MDA-MB-435 (GRPR(-)/integrin alpha(v)beta(3)(+)) breast cancer models. The three radiotracers all possessed in vitro dual integrin alpha(v)beta(3) and GRPR binding affinity. The advantages of the RGD-BBN radiotracers over the corresponding BBN analogues are obvious for imaging MDA-MB-435 (GRPR(-)/integrin alpha(v)beta(3)(+)) tumor. (18)F-FB-PEG(3)-RGD-BBN showed lower tumor uptake than (64)Cu-NOTA-RGD-BBN and (68)Ga-NOTA-RGD-BBN but was able to visualize breast cancer tumors with high contrast. Synthesis of (64)Cu-NOTA-RGD-BBN and (68)Ga-NOTA-RGD-BBN is much faster and easier than (18)F-FB-PEG(3)-RGD-BBN. (64)Cu-NOTA-RGD-BBN showed prolonged tumor uptake but also higher liver retention and kidney uptake than (68)Ga-NOTA-RGD-BBN and (18)F-FB-PEG(3)-RGD-BBN. (68)Ga-NOTA-RGD-BBN possessed high tumor signals but also relatively high background uptake compared with the other two radiotracers. In summary, the prosthetic labeling groups, chelators, and isotopes all have a profound effect on the tumor targeting efficacy and in vivo kinetics of the RGD-BBN tracers for dual integrin and GRPR recognition. Further development of suitably labeled RGD-BBN tracers for PET imaging of cancer is warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20540537      PMCID: PMC2895820          DOI: 10.1021/bc9000245

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  51 in total

1.  microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.

Authors:  Yun Wu; Xianzhong Zhang; Zhengming Xiong; Zhen Cheng; Darrell R Fisher; Shuang Liu; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

2.  MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor.

Authors:  Jesse J Parry; Rebecca Andrews; Buck E Rogers
Journal:  Breast Cancer Res Treat       Date:  2006-07-13       Impact factor: 4.872

3.  The proteome of the human breast cancer cell line MDA-MB-231: Analysis by LTQ-Orbitrap mass spectrometry.

Authors:  Vaïk Strande; Ludovic Canelle; Christophe Tastet; Odile Burlet-Schiltz; Bernard Monsarrat; Hubert Hondermarck
Journal:  Proteomics Clin Appl       Date:  2008-12-09       Impact factor: 3.494

4.  Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects.

Authors:  Weibo Cai; Dong-Woon Shin; Kai Chen; Olivier Gheysens; Qizhen Cao; Shan X Wang; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  Nano Lett       Date:  2006-04       Impact factor: 11.189

Review 5.  Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.

Authors:  D B Cornelio; R Roesler; G Schwartsmann
Journal:  Ann Oncol       Date:  2007-03-09       Impact factor: 32.976

6.  (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.

Authors:  Zi-Bo Li; Weibo Cai; Qizhen Cao; Kai Chen; Zhanhong Wu; Lina He; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2007-06-15       Impact factor: 10.057

7.  Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients.

Authors:  F Scopinaro; A D Varvarigou; W Ussof; G De Vincentis; T G Sourlingas; G P Evangelatos; J Datsteris; S C Archimandritis
Journal:  Cancer Biother Radiopharm       Date:  2002-06       Impact factor: 3.099

Review 8.  Multimodality imaging of tumor integrin alphavbeta3 expression.

Authors:  Xiaoyuan Chen
Journal:  Mini Rev Med Chem       Date:  2006-02       Impact factor: 3.862

9.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

10.  Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.

Authors:  Jered C Garrison; Tammy L Rold; Gary L Sieckman; Farah Naz; Samantha V Sublett; Said Daibes Figueroa; Wynn A Volkert; Timothy J Hoffman
Journal:  Bioconjug Chem       Date:  2008-08-20       Impact factor: 4.774

View more
  43 in total

Review 1.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Replacement of the Lys linker with an Arg linker resulting in improved melanoma uptake and reduced renal uptake of Tc-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide.

Authors:  Jianquan Yang; Haixun Guo; R Steve Padilla; Marianne Berwick; Yubin Miao
Journal:  Bioorg Med Chem       Date:  2010-08-01       Impact factor: 3.641

Review 3.  Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.

Authors:  Allen F Brooks; Lindsey R Drake; Megan N Stewart; Brian P Cary; Isaac M Jackson; Dale Mallette; Andrew V Mossine; Peter J H Scott
Journal:  Pharm Pat Anal       Date:  2015-12-16

Review 4.  Peptides and peptide hormones for molecular imaging and disease diagnosis.

Authors:  Seulki Lee; Jin Xie; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 5.  Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities.

Authors:  Zhiyong Wang; Gang Liu; Hairong Zheng; Xiaoyuan Chen
Journal:  Biotechnol Adv       Date:  2013-09-05       Impact factor: 14.227

6.  Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.

Authors:  Jingjing Zhang; Gang Niu; Lixin Lang; Fang Li; Xinrong Fan; Xuefeng Yan; Shaobo Yao; Weigang Yan; Li Huo; Libo Chen; Zhiyuan Li; Zhaohui Zhu; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2016-08-04       Impact factor: 10.057

7.  Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.

Authors:  Rajendra Prasad Bandari; Zongrun Jiang; Tamila Stott Reynolds; Nicole E Bernskoetter; Ashley F Szczodroski; Kurt J Bassuner; Daniel L Kirkpatrick; Tammy L Rold; Gary L Sieckman; Timothy J Hoffman; James P Connors; Charles J Smith
Journal:  Nucl Med Biol       Date:  2014-01-10       Impact factor: 2.408

8.  In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.

Authors:  Senthil R Kumar; Fabio A Gallazzi; Riccardo Ferdani; Carolyn J Anderson; Thomas P Quinn; Susan L Deutscher
Journal:  Cancer Biother Radiopharm       Date:  2010-12       Impact factor: 3.099

Review 9.  Peptide-based imaging agents for cancer detection.

Authors:  Xiaolian Sun; Yesen Li; Ting Liu; Zijing Li; Xianzhong Zhang; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2016-06-18       Impact factor: 15.470

Review 10.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.